THE LEVELS OF PLASMINOGEN AND INHIBITOR OF PLASMINOGEN ACTIVATORS OF TYPE 1 IN ANTIPHOSPHOLIPID SYNDROME
- Authors: Ostryakova EV1, Reshetnyak TM1, Aisina RB2, Mukhametova LI2, Gulin DA2, Alexandrova EN1, Seredavkina NV1, Varfolomeev SD3, Chernyakov AV4, Nikiforov Y.V5, Nasonov EL1
-
Affiliations:
- Research Institute of Rheumatology
- M.V. Lomonosov State University
- N.M. Emmanuel Institute of Biochemical Physics
- N.I. Pirogov Russian Medical University
- O.M. Filatov City hospital № 15
- Issue: Vol 84, No 5 (2012)
- Pages: 50-57
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31046
- ID: 31046
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
E V Ostryakova
Research Institute of Rheumatology
Email: katerina.ostryakova@yandex.ru
аспирант НИИР РАМН
T M Reshetnyak
Research Institute of Rheumatology
R B Aisina
M.V. Lomonosov State University
L I Mukhametova
M.V. Lomonosov State University
D A Gulin
M.V. Lomonosov State University
E N Alexandrova
Research Institute of Rheumatology
N V Seredavkina
Research Institute of Rheumatology
S D Varfolomeev
N.M. Emmanuel Institute of Biochemical Physics
A V Chernyakov
N.I. Pirogov Russian Medical University
Yu V Nikiforov
O.M. Filatov City hospital № 15
E L Nasonov
Research Institute of Rheumatology
References
- Насонов Е. Л. Антифосфолипидный синдром. М.: Литтерра; 2004.
- Ruiz-Irastorza G., Crowther M., Branch W., Khamashta M. A. Antiphospholipid syndrome. Lancet 2010; 376: 1498—1509.
- Mehdi A. A., Uthman I., Khamashta M. Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future. Eur. J. Clin. Invest. 2010; 40: 451—464.
- Myakis S., Lockshin M. D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J. Thromb. Haemost. 2006; 4: 295—306.
- Решетняк Т. М., Вавилова Т. В. Клинико-лабораторные критерии диагностики антифосфолипидного синдрома — что нужно знать практическому врачу (лекция). Клин. лаб. диагн. 2010; 5: 12—22.
- Chen P. P., Giles I. Antibodies to serine proteases in the atiphospholipid syndrome. Curr. Rheumatol. Rep. 2010; 12: 45—52.
- Lisman T., de Groot P. G., Meijers J. C. M., Rosendaal F. R. Reduced plasma fibrinolytic potential is a risk factor foe venous thrombosis. Blood 2005; 105: 1102—1105.
- Smalberg J. H., Kruip M. J. H.A., Janssen H. L. A. et al. Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis. Arterioscler. Thromb. Vas. Bol. 2011; 31: 485—493.
- Brandt J. T., Triplett D. A., Alving B., Scharrer I. Criteria for the diagnosis of lupus anticoatulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant / Antiphospholipid Antibodies of the Scientific and Standardization Committee of the ISTH. Thromb. Haemost. 1995; 74: 1185—1190.
- Brandt J. T., Barna L. K., Triplett D. A. Laboratory identification of lupus anticoaulants: results of the Second International Workshop for identification of lupus anticoagulants. Thromb. Haemost. 1995; 74: 1597—1603.
- Баркаган З. С., Момот А. П. Диагностика и контролируемая терапия нарушений гемостаза. М.: Ньюдиамед; 2001.
- Александрова Е. Н., Новиков А. А., Решетняк Т. М. и др. Диагностическое и прогностическое значение антител к кардиолипину, b2-гликопротеину-1 и протромбину при антифосфолипидном синдроме. Клинико-лаб. консилиум 2009; 2: 47—58.
- Левашов М. Ю., Айсина Р. Б., Гершкович К. Б., Варфоломеев С. Д. Механизм действия ω-аминокислот на активацию плазминогена и фибринолиз, инициированные стафилокиназой. Биохимия 2007; 72 (7): 872—882.
- Айсина Р. Б., Мухаметова Л. И., Гулин Д. А. и др. Ингибирующее действие ангиостатинов на активность системы плазминоген/активаторы плазминогена. Биохимия 2009; 74 (10): 1356—1367.
- Miles L. A., Plow E. F. Cellular regulation of fibrinolysis. Thromb. Haemost. 1991; 66: 32—36.
- Hajjar K. A. The molecular basis of fibrinolysis. In: Hematology of infancy and childhood. Philadelphia; 2003. 1497—1514.
- Долгов В. В., Свирин П. В. Лабораторная диагностика нарушений гемостаза. М.; Тверь: Триада; 2005.
- Cesarman-Maus G., Hajjar K. A. Molecular mechanisms of fibrinolysis. Br. J. Haematol. 2005; 129: 307—321.
- Hoover-Plow J. Does plasmin have anticoagulant activity? Vasc. Hlth Risk Manag. 2010; 6: 199—205.
- Pizzo S. V., Schwartz M. L., Hill R. L., McKee P.A. The effect of plasmin on the subunit structure of human fibrin. J. Biol. Chem. 1973; 248: 4574—4583.
- Hajjar K. A., Harpel P. C., Jaffe E. A., Nachman R. L. Binding of plasminogen to cultured human endothelial cells. J. Biol. Chem. 1986; 261: 11656—11662.
- Myöhänen H., Vaheri A. Regulation and interactions in the activation of cell-associated plasminogen. Cell. Mol. Life Sci. 2004; 61: 2840—2858.
- Hoylaerts M., Rijken D. C., Lijnen H. R. et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J. Biol. Chem. 1982; 257: 2912—2929.
- Levin E. G., del Zoppo G. J. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am. J. Pathol. 1994; 144: 855—861.
- Saksela O. Plasminogen activation and regulation of proteolysis. Biochim. Biophys. Acta 1985; 823: 35—65.
- Binder B. R. Physiology and pathophysiology of the fibrinoliytic system. Fibrinolysis 1995; 9 (Suppl. 1): 3—8.
- Lijnen H. R., Zamarron C., Blaber M. et al. Activation of plasminogen by pro-urokinase. J. Biol. Chem. 1986; 261: 1253—1258.
- Sartori M. T., Simioni P., Patrassi G. M. et al. Combined heterozygous plasminogen deficiency and factor V leiden defect in the same kindred. Thromb. Hemost. 2000; 6 (1): 36—40.
- Bugge T. H., Flick M. J., Daugherty C. C., Degen J. L. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes and Dev. 1995; 9: 794—807.
- Robbins K. C. Classification of abnormal plasmingens: dysplasminogenemias. Semin. Thromb. Haemost. 1990; 16: 217—220.
- Aoki N., Moroi M., Sakata Y. et al. Abnormal plasminogen: a hereditary molecular abnormality found in a patient with recurrent thrombosis. J. Clin. Invest. 1978; 61: 1186—1195.
- Sulzer I., Stucki B. Is plasminogen deficiency a thrombotic risk factor? A study on 23 thrombophilic patients and their family members. Thromb. Haemost. 1998; 80 (1): 167—170.
- Tait R. C., Walker I. D., Conkie J. A. Isolated familial plasminogen deficiency may not be a risk factor for thrombosis. Thromb. Haemost 1996; 76 (6): 1004—1008.
- Zorio E., Gilabert-Estelles J., España F. et al. Fibrinolysis: the key to new pathogenetic mechanisms. Curr. Med. Chem. 2008; 15: 923—929.
- Kohler H. P., Grant P. G. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 2000; 342: 1792—1801.
- Eren M., Painter C. A., Atkinson J. B. et al. Age-dependent spontaneous coronary arterial thrombosis in transgenic mise that express a stable form of human plasminogen-activator inhibitor-1. Circulation 2002; 106: 491—496.
- Sobel B. E., Woodcock-Mitchell J., Schneider D. J. et al. Increased plasminogen-activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients. Circulation 1998; 97: 2213—2221.
- Kaitita K., Schoenhard J. A., Painter C. A. et al. Potential roles of plasminogen-activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibitor. J. Mol. Cell. Cardiol. 2002; 34: 617—627.
- Mottonen J., Strand A., Symersky J. et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270—273.
- Samad F., Yamamoto K., Loskutoff D. J. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. J. Clin. Invest. 1996; 97: 37—46.
- Forastiero R., Martinuzzo M. Antigen specificity and clinical relevance of antiphospholipid syndrome-related autoantibodies. Curr. Rheumatol. Rev. 2005; 1: 177—187.
- Forastiero R., Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus 2008; 17: 872—877.
- Jurado M., Paramo J. A., Gutierrez-Pimentel M., Rocha E. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other tissue disorders. Thromb. Haemost. 1992; 68: 516—520.
- Ames P. R. J., Tommasino C., Iannaccone L. et al. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic an-tiphosopholipid antibodies ? a crucial role for acquired free protein S deficiency. Thromb. Haemost. 1996; 75: 190—194.